Northgate (301333) 2023 Report and 2024 Quarterly Report Review: Revenue Growth Steady, Short-term Profit Under Pressure Due to Amortization of Equity Incentives
Norsk (301333): Stable revenue growth, profits are under short-term pressure due to equity incentives and amortization
Caixin Securities released a research report on April 25 stating that it gave Norsger (301333.SZ) an increase in holdings rating. The main reasons for the rating include: 1) incident: the company released the 2023 annual report and the first quarter repor
Norsk (301333): Increased profitability and continued order growth help long-term development
Norske (301333): Steady growth in clinical operations and SMO is optimistic about increasing market share of high-quality clinical CRO
Norsk (301333): Strong growth in performance, significant increase in profit margins
Norsig (301333): Profit levels maintain steady growth, brand advantages help expand orders
Norsig (301333): New orders continue to increase, profit growth exceeds expectations
Norsig (301333): Steady revenue growth in the first three quarters and gradual release of profit elasticity
Norsig (301333) 2023 Q3 Report Commentary: Profit Side Achieves High Growth
Northgate (301333): A rapidly growing, all-round, full-chain clinical CRO service provider
Northegg (301333) 2023 Interim Report Review: Performance is growing steadily, and new orders are plentiful
Norsig (301333): Performance growth is in line with expectations, new orders are growing rapidly
Norsig (301333): New orders have increased by nearly 70%, and future growth can be expected
Northgard (301333): Deeply involved in clinical CRO business, full-service drug clinical development
Northgard (301333): The growth rate slows down under the turmoil of the epidemic, and long-term growth in clinical CRO can be expected
Northgard (301333): IPO Sorting
No Data